About NewAmsterdam Pharma Company NV
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: NL
- Website: https://ir.newamsterdampharma.com/
Frequently Asked Questions
What is the 52-week range for NAMS?
The 52-week high is $42.205 and the 52-week low is $21.02.
What is the P/E ratio for NAMS?
The P/E ratio data is currently unavailable.
What is the dividend yield for NAMS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -38.33%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3644.21%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.82.
Analyst Recommendation Trends
Wall Street analyst consensus for NAMS over the last few months:
Latest NAMS News
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Activists also report to the SEC on NewAmsterdam Pharma, Tennant, Colliers International Group, and Kinetik Holdings.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat
NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-- The study will evaluate changes in blood-based
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals. The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called […]
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C - NAARDEN, The Netherlands and MIAMI and FLORENCE, Italy, Sept. 21, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “
NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company’s book value. With the stock now some distance below its earlier highs, the issue is whether the balance sheet still backs up where the price sits today. Over the past 3 years, NewAmsterdam Pharma has returned about 139%, which now puts real pressure on the numbers to show that book value keeps...
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.
Novartis Trial Failure Sparks Biopharma Options Frenzy
3 biopharma stocks seeing high options volume
NewAmsterdam Pharma: Potential Coupled With Uncertainty
NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merckâs Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target
HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $52 price target.
Curious about the stocks that are showing activity after the closing bell on Monday?
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter | -50,246 | - | - |
| 2026-09-30 | Kastelein Johannes Jacob Pieter | -50,246 | $25.03 | $1,257,657 |
| 2026-09-30 | Kastelein Johannes Jacob Pieter | +50,246 | - | - |
| 2026-09-14 | Davidson Michael H. | +10,000 | $22.65 | $226,500 |
| 2026-09-04 | Smither John W | -1,600 | $25.32 | $40,512 |
| 2026-09-01 | Gunning Robert William | +14,000 | - | - |
| 2026-09-01 | Gunning Robert William | +3,200 | - | - |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | -125,000 | - | - |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | -125,000 | $26.91 | $3,363,750 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | +125,000 | - | - |
| 2026-07-20 | Kooij Louise Frederika | -80,000 | - | - |
| 2026-07-20 | Kooij Louise Frederika | -25,000 | - | - |
| 2026-07-20 | Kooij Louise Frederika | -2,915 | $31.71 | $92,435 |
| 2026-07-20 | Kooij Louise Frederika | -31,885 | $31.05 | $990,029 |
| 2026-07-20 | Kooij Louise Frederika | -70,200 | $29.96 | $2,103,192 |
| 2026-07-20 | Kooij Louise Frederika | +80,000 | $11.17 | $893,600 |
| 2026-07-20 | Kooij Louise Frederika | +25,000 | $11.9 | $297,500 |
| 2026-06-22 | Kooij Louise Frederika | -15,000 | - | - |
| 2026-06-22 | Kooij Louise Frederika | -25,000 | - | - |
| 2026-06-22 | Kooij Louise Frederika | -300 | $30.73 | $9,219 |
| 2026-06-22 | Kooij Louise Frederika | -39,700 | $30.2 | $1,198,940 |
| 2026-06-22 | Kooij Louise Frederika | +15,000 | $11.9 | $178,500 |
| 2026-06-22 | Kooij Louise Frederika | +25,000 | $10.9 | $272,500 |
| 2026-05-26 | Kooij Louise Frederika | -5,000 | - | - |
| 2026-05-26 | Kooij Louise Frederika | -60,000 | - | - |
| 2026-05-26 | Kooij Louise Frederika | -65,000 | $35.69 | $2,319,850 |
| 2026-05-26 | Kooij Louise Frederika | +5,000 | $10.9 | $54,500 |
| 2026-05-26 | Kooij Louise Frederika | +60,000 | $10 | $600,000 |
| 2026-03-11 | LANGE LOUIS G | -446 | $31.23 | $13,929 |
| 2026-03-11 | LANGE LOUIS G | -44,173 | $30.41 | $1,343,301 |
| 2026-03-09 | LANGE LOUIS G | -44,619 | - | - |
| 2026-03-09 | LANGE LOUIS G | +44,619 | $11.5 | $513,119 |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | -101,409 | - | - |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | -101,409 | $30.29 | $3,071,679 |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | +101,409 | - | - |
| 2026-03-06 | LANGE LOUIS G | -28,186 | $29.41 | $828,950 |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | -94,124 | - | - |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | -94,124 | $30.32 | $2,853,840 |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | +94,124 | - | - |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | -104,467 | - | - |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | -104,467 | $30.3 | $3,165,350 |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | +104,467 | - | - |
| 2026-03-02 | Davidson Michael H. | -443,707 | - | - |
| 2026-03-02 | Davidson Michael H. | -443,707 | $33.25 | $14,753,258 |
| 2026-03-02 | Davidson Michael H. | +443,707 | - | - |
| 2026-02-26 | Davidson Michael H. | -183,332 | - | - |
| 2026-02-26 | Davidson Michael H. | -17,924 | $34.44 | $617,303 |
| 2026-02-26 | Davidson Michael H. | -165,408 | $33.63 | $5,562,671 |
| 2026-02-26 | Davidson Michael H. | +183,332 | - | - |
| 2026-02-25 | Davidson Michael H. | -58,253 | - | - |
| 2026-02-25 | Davidson Michael H. | -1,300 | $36.68 | $47,684 |
| 2026-02-25 | Davidson Michael H. | -10,436 | $35.96 | $375,279 |
| 2026-02-25 | Davidson Michael H. | -46,517 | $35.11 | $1,633,212 |
| 2026-02-25 | Davidson Michael H. | +58,253 | - | - |
| 2026-02-24 | Davidson Michael H. | -64,708 | - | - |
| 2026-02-24 | Davidson Michael H. | -3,161 | $36.46 | $115,250 |
| 2026-02-24 | Davidson Michael H. | -61,547 | $36.13 | $2,223,693 |
| 2026-02-24 | Davidson Michael H. | +64,708 | - | - |
| 2026-02-20 | Kastelein Johannes Jacob Pieter | -30,789 | $35.46 | $1,091,778 |
| 2026-02-20 | Kastelein Johannes Jacob Pieter | -14,692 | $35 | $514,220 |
| 2026-01-28 | Kooij Louise Frederika | -32,612 | - | - |
| 2026-01-28 | Kooij Louise Frederika | -32,612 | $31.8 | $1,037,062 |
| 2026-01-28 | Kooij Louise Frederika | +32,612 | $10.9 | $355,471 |
| 2026-01-27 | Kooij Louise Frederika | -39,816 | - | - |
| 2026-01-27 | Kooij Louise Frederika | -39,816 | $32.62 | $1,298,798 |
| 2026-01-27 | Kooij Louise Frederika | +39,816 | $10.9 | $433,994 |
| 2026-01-26 | Kooij Louise Frederika | -34,400 | - | - |
| 2026-01-26 | Kooij Louise Frederika | -309 | $33.45 | $10,336 |
| 2026-01-26 | Kooij Louise Frederika | -34,091 | $32.77 | $1,117,162 |
| 2026-01-26 | Kooij Louise Frederika | +34,400 | $10.9 | $374,960 |
| 2026-01-23 | Kooij Louise Frederika | -38,172 | - | - |
| 2026-01-23 | Kooij Louise Frederika | -12,767 | $34.37 | $438,802 |
| 2026-01-23 | Kooij Louise Frederika | -25,405 | $33.44 | $849,543 |
| 2026-01-23 | Kooij Louise Frederika | +38,172 | $10.9 | $416,075 |
| 2026-01-21 | Somaiya Mayur Ian | -39,784 | - | - |
| 2026-01-21 | Somaiya Mayur Ian | -24,362 | $33.8 | $823,436 |
| 2026-01-21 | Somaiya Mayur Ian | -15,422 | $33.25 | $512,782 |
| 2026-01-21 | Somaiya Mayur Ian | +39,784 | $9.26 | $368,400 |
| 2026-01-20 | Somaiya Mayur Ian | -60,216 | - | - |
| 2026-01-20 | Somaiya Mayur Ian | -19,604 | $32.38 | $634,778 |
| 2026-01-20 | Somaiya Mayur Ian | -39,712 | $31.78 | $1,262,047 |
| 2026-01-20 | Somaiya Mayur Ian | -900 | $30.64 | $27,576 |
| 2026-01-20 | Somaiya Mayur Ian | +60,216 | $9.26 | $557,600 |
| 2026-01-07 | van der Kamp Hilde Johanna | +15,300 | - | - |
| 2026-01-07 | van der Kamp Hilde Johanna | +3,400 | - | - |
| 2026-01-07 | McKenna Mark C. | +15,300 | - | - |
| 2026-01-07 | McKenna Mark C. | +3,400 | - | - |
| 2026-01-07 | Gulfo Adele M. | +15,300 | - | - |
| 2026-01-07 | Gulfo Adele M. | +3,400 | - | - |
| 2026-01-07 | Davidson Michael H. | +364,000 | - | - |
| 2026-01-07 | Davidson Michael H. | +81,000 | - | - |
| 2026-01-07 | Davidson Michael H. | -11,582 | - | - |
| 2026-01-07 | Smither John W | +15,300 | - | - |
| 2026-01-07 | Smither John W | +3,400 | - | - |
| 2026-01-07 | Lewis William | +15,300 | - | - |
| 2026-01-07 | Lewis William | +3,400 | - | - |
| 2026-01-07 | LANGE LOUIS G | +15,300 | - | - |
| 2026-01-07 | LANGE LOUIS G | +3,400 | - | - |
| 2026-01-07 | Kastelein Johannes Jacob Pieter | +115,000 | - | - |
| 2026-01-07 | Kastelein Johannes Jacob Pieter | +25,500 | - | - |
| 2026-01-07 | Kooij Louise Frederika | +53,500 | - | - |
| 2026-01-07 | Kooij Louise Frederika | +12,000 | - | - |
| 2026-01-07 | Somaiya Mayur Ian | +115,000 | - | - |
| 2026-01-07 | Somaiya Mayur Ian | +25,500 | - | - |
| 2026-01-05 | Kastelein Johannes Jacob Pieter | -6,000 | $33.25 | $199,500 |
| 2026-01-05 | Kooij Louise Frederika | -2,647 | $33.25 | $88,013 |
| 2026-01-05 | Somaiya Mayur Ian | -5,118 | $33.25 | $170,174 |
| 2025-12-26 | Kooij Louise Frederika | -5,000 | - | - |
| 2025-12-26 | Kooij Louise Frederika | -38,872 | - | - |
| 2025-12-26 | Kooij Louise Frederika | -43,872 | $35.3 | $1,548,682 |
| 2025-12-26 | Kooij Louise Frederika | +5,000 | $10.9 | $54,500 |
| 2025-12-26 | Kooij Louise Frederika | +38,872 | $10 | $388,720 |
| 2025-12-24 | Kooij Louise Frederika | -26,011 | - | - |
| 2025-12-24 | Kooij Louise Frederika | -26,011 | $35.68 | $928,072 |
| 2025-12-24 | Kooij Louise Frederika | +26,011 | $10 | $260,110 |
| 2025-12-23 | Kooij Louise Frederika | -75,117 | - | - |
| 2025-12-23 | Kooij Louise Frederika | -75,117 | $36.21 | $2,719,987 |
| 2025-12-23 | Kooij Louise Frederika | +75,117 | $10 | $751,170 |